Phase 1 Multicenter, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab-Naive Subjects with Grade IV Malignant Glioma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Celgene Research and Development
Start Date
April 1, 2015
End Date
September 22, 2021
Administered By
Duke Cancer Institute
Awarded By
Celgene Research and Development
Start Date
April 1, 2015
End Date
September 22, 2021